Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: April 2013

Chicago’s the Place for NJ’s Latest Efforts to Attract Life Sciences Business

Somerset, NJ, April 25, 2013NJBIZ’s Mary Ann Bourbeau reports The state’s ongoing efforts to lure businesses to New Jersey hit the road to Chicago this week, to attend the BIO International Convention, an event that drew more than 16,500 industry leaders from 65 countries last year.

Choose New Jersey is leading a delegation that includes Lt. Gov. Kim Guadagno, the Business Action Center, BioNJ, the HealthCare Institute of New Jersey (HINJ), and several universities and health care companies to showcase New Jersey as one of the world’s premiere locations for life science companies and medical research.   Continue reading

Choose New Jersey and Partners Promote NJ as Global Life Science Hub at World’s Largest Biotechnology Event

Chicago, IL, April 23, 2013 — To showcase New Jersey as one of the world’s premiere locations for life science companies and medical research, Choose New Jersey, Inc. is collaborating with Lt. Governor Kim Guadagno, the Business Action Center (BAC), the HealthCare Institute of New Jersey (HINJ), BioNJ and other partners at the BIO International Convention in Chicago on April 22-25, 2013. Continue reading

Democrats Eye Pharma Industry in Push for Medicare Cuts; PhRMA Responds Strongly

Washington, DC, April 17, 2013 — According to The Hill, Congressional Democrats ratcheted up a years-long feud with the pharmaceutical industry Tuesday as they proposed significant cuts in Medicare’s payments to drug companies.  The Pharmaceutical Research and Manufacturers Of America (PhRMA) was quick to respond.

The Hill reported that Democrats in both the House and Senate will introduce bills this week to lower drug prices for the poorest seniors, saving the government roughly $140 billion in Medicare costs. Continue reading

Rep. Sires Commends NJ Life Sciences Industry’s Post-Sandy Contributions to the Community

Washington, DC, April 16, 2013 — U.S. Representative Albio Sires (D-8) on April 11 rose on the floor of the United States House of Representatives to “commend the contributions of the biopharmaceutical and medical technology companies in New Jersey to Hurricane Sandy relief activities.”  Congressman Sires stated: Continue reading

New PhRMA Chairman Bob Hugin Looks to the Future

Washington, DC, April 15, 2013 — Robert J. Hugin, Chairman and CEO of Celgene Corporation and newly elected Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) Board of Directors, writes that PhRMA’s annual conference last week was “an excellent reminder of the accomplishments of our organization during the past year under the leadership of Dr. John Lechleiter.”

“We have made important progress in our ongoing mission to protect and expand medical innovation and provide patients with access to disease-altering new therapies,” Mr. Hugin said.  “These sessions have also instilled tremendous confidence that we will continue this vital work as we navigate an increasingly challenging policy environment.” Continue reading

Celgene’s Robert J. Hugin Elected PhRMA Board Chairman

Washington, DC, April 15, 2013 — Robert J. Hugin, Chairman and CEO of Celgene Corporation, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) on April 12 at the trade association’s annual meeting, which was held in San Diego.

Mr. Hugin succeeds John C. Lechleiter, Ph.D., Chairman, President, and CEO of Eli Lilly and Company.

In addition, PhRMA announced that Ian C. Read, President and CEO of Pfizer Inc, as chairman-elect of the PhRMA Board of Directors, and Kenneth C. Frazier, Chairman, President and CEO of Merck & Co, Inc., as Board Treasurer. Continue reading

Washington Post: President’s Budget Is Disaster for Drugmakers

Washington, DC, April 15, 2013The Washington Post’s Sarah Kliff reports that Brad Plumer wrote last week wrote about how pharmaceutical companies were one of the biggest losers in President Barack Obama’s proposed Fiscal Year 2014 budget.  This BGov graph shows how much, exactly, they’re losing by — a lot. 

Kliff reports that the Obama budget cuts for pharmaceuticals work out to $164 billion, just under half the total health-care budget cuts the president is seeking.  Most of this grows out of the White House proposal to change the way  Medicare pays for drugs to make it look more like the Medicaid program. Continue reading

Report: PhRMA Member Companies Invested $48.5 Billion in R&D in 2012

Washington, DC, April 12, 2013 —Investment in research and development (R&D) by member companies of the Pharmaceutical Research and Manufacturers of America (PhRMA) remained strong at an estimated $48.5 billion in 2012, despite economic, scientific, and business challenges.  These efforts are highlighted in PhRMA’s 2013 Biopharmaceutical Research Industry Profile released on Thursday. Continue reading

President Proposes Cuts to Healthcare Industries; Life Sciences Industry Responds

Washington, DC, April 11, 2013 — Yesterday, President Obama unveiled his Fiscal Year 2014 proposed budget, which includes deep cuts in Medicare payments to pharmaceutical companies, hospitals and nursing homes.  Obama’s budget includes roughly $400 billion in healthcare savings — the vast majority of which come from cuts to healthcare providers, rather than changes in benefits.

According to The Hill, the pharmaceutical industry would take a hit of nearly $150 billion under Obama’s budget.  The President proposed steep cuts in the prices Medicare pays for prescription drugs, as well as policies that would speed cheaper generic drugs to market more quickly. Continue reading

Christie Administration Receives National Business Retention Award from Business Facilities Magazine

Trenton, NJ, April 9, 2013 — For the second year in a row, Business Facilities Magazine has recognized the Christie Administration’s success at improving Garden State’s business climate, by selecting the New Jersey Partnership for Action for its Achievement in Business Retention Award.  

This year’s award recognizes the work undertaken by the Christie Administration through the New Jersey Partnership for Action (PFA) to make the state a home for economic development and growth.   Continue reading